Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
escalated BEACOPP + goserelin
- Development stage
- Unknown
- Lead developer
- German Hodgkin Study Group
- Modality
- Peptides, Small Molecules
- Administration
- Intravenous, Oral, Subcutaneous
01
Overview
This combination regimen consists of the escalated BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) chemotherapy protocol administered alongside goserelin, a gonadotropin-releasing hormone (GnRH) agonist. Developed and studied by the University of Cologne and the German Hodgkin Study Group (GHSG) in the PROFE trial, the regimen was designed to treat advanced-stage Hodgkin lymphoma while investigating the potential of goserelin to protect ovarian function and reduce treatment-induced infertility in fertile women. Goserelin works by temporarily suppressing the pituitary-gonadal axis, theoretically placing the ovaries in a quiescent state to shield them from the cytotoxic effects of chemotherapy. However, results from the PROFE trial indicated that goserelin did not significantly reduce ovarian toxicity compared to oral contraceptives in this specific setting.
- Brand names
- Zoladex
- Other names
- bleomycin + etoposide + doxorubicin + cyclophosphamide + vincristine + procarbazine + prednisone + goserelinescalated BEACOPP plus goserelin
02
Targets
GnRHR (Gonadotropin-releasing hormone receptor)
Beyond the preview
Go deeper on escalated BEACOPP + goserelin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on escalated BEACOPP + goserelin.